CVS Health Co. (NYSE:CVS) Receives $71.94 Consensus Price Target from Analysts

Shares of CVS Health Co. (NYSE:CVSGet Free Report) have been given a consensus rating of “Moderate Buy” by the twenty ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $71.47.

Several research analysts have recently weighed in on CVS shares. Morgan Stanley reaffirmed an “overweight” rating on shares of CVS Health in a report on Tuesday, April 15th. Evercore ISI raised their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. StockNews.com raised CVS Health from a “sell” rating to a “hold” rating in a report on Thursday, February 13th. Truist Financial raised their target price on shares of CVS Health from $76.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, April 11th. Finally, Piper Sandler increased their price target on shares of CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday, March 21st.

Get Our Latest Analysis on CVS

Insider Buying and Selling

In other CVS Health news, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of CVS Health stock in a transaction on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.22% of the company’s stock.

Institutional Investors Weigh In On CVS Health

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Ridgewood Investments LLC lifted its position in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 450 shares during the last quarter. Stonebridge Financial Group LLC purchased a new stake in CVS Health in the fourth quarter valued at $28,000. Hopwood Financial Services Inc. acquired a new position in CVS Health in the fourth quarter valued at $29,000. McIlrath & Eck LLC grew its holdings in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 174 shares during the last quarter. Finally, Sierra Ocean LLC increased its position in shares of CVS Health by 584.8% during the first quarter. Sierra Ocean LLC now owns 719 shares of the pharmacy operator’s stock worth $49,000 after purchasing an additional 614 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Trading Up 4.1 %

Shares of CVS Health stock opened at $69.42 on Tuesday. The firm has a market cap of $87.52 billion, a PE ratio of 18.97, a P/E/G ratio of 0.98 and a beta of 0.57. CVS Health has a 1 year low of $43.56 and a 1 year high of $72.51. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The stock has a fifty day moving average price of $66.64 and a 200-day moving average price of $58.87.

CVS Health (NYSE:CVSGet Free Report) last announced its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. During the same quarter last year, the firm posted $1.31 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts anticipate that CVS Health will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.83%. CVS Health’s dividend payout ratio (DPR) is 72.68%.

CVS Health Company Profile

(Get Free Report

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Stories

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.